CERo Therapeutics Holdings Past Earnings Performance
Past criteria checks 0/6
CERo Therapeutics Holdings has been growing earnings at an average annual rate of 118.4%, while the Biotechs industry saw earnings growing at 19.3% annually.
Key information
118.4%
Earnings growth rate
46.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How CERo Therapeutics Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -5 | 9 | 2 |
| 30 Jun 24 | 0 | -3 | 6 | 1 |
| 31 Mar 24 | 0 | -2 | 5 | 0 |
| 31 Dec 23 | 0 | -3 | 3 | 0 |
| 30 Sep 23 | 0 | -6 | 4 | 4 |
| 30 Jun 23 | 0 | -5 | 5 | 2 |
| 31 Mar 23 | 0 | -3 | 4 | 1 |
| 31 Dec 22 | 0 | -1 | 3 | 0 |
| 30 Sep 22 | 0 | -37 | 2 | 0 |
Quality Earnings: CERO is currently unprofitable.
Growing Profit Margin: CERO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CERO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CERO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CERO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: CERO's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.